Cyclocopacamphan-12-ol (epimer B) is a trace-to-minor oxygenated sesquiterpene alcohol associated most strongly with vetiver root oil, especially Indian, Java, and related commercial vetiver profiles. The strongest evidence for this constituent is analytical rather than pharmacological: NIST and PubChem define the stereoisomer, PubMed-indexed vetiver composition work names the cyclocopacamphan-12-ol epimers as characteristic odor contributors, and AromaForge oil records show repeat occurrence around the 1% to 3% range in vetted GC-MS reports. Direct isolated bioactivity or human-use evidence specific to epimer B was not located in this pass, so archive copy should frame it as a vetiver identity and aroma marker rather than a wellness-active constituent.
Chemical identity and composition
NIST lists the epimer B stereoisomer separately from the parent cyclocopacamphan-12-ol entry and gives the same molecular formula, C15H24O, with a distinct stereochemical InChIKey. In the AromaForge archive, epimer B recurs across multiple vetiver records and sits within the broader zizaane-rich oxygenated sesquiterpene fraction that helps define vetiver's odor fingerprint.
Aroma and practical use
- Use the recorded woody, earthy, vetiver-like, dry descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
south indian vetiver occurrence
A 2012 vetiver composition paper reported that cyclocopacamphan-12-ol epimers A and B are among the important compounds that impart the characteristic odor of south Indian vetiver oils.
Measured: named occurrence within characteristic odor-contributor set
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
archive vetiver batch occurrence
AromaForge oil records based on directly readable GC-MS reports place cyclocopacamphan-12-ol epimer B around 1.28% in one Indian vetiver batch and 2.78% in one Madagascar-profiled vetiver batch used as context for Papuan red vetiver.
Measured: quantified presence in vetted vetiver batches
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA standard, RIFM safety assessment, or human tolerability study specific to cyclocopacamphan-12-ol epimer B was located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible evidence is dominated by identity and occurrence data, archive copy should avoid therapeutic, anti-inflammatory, or other biological claims for the isolated stereoisomer.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Handling language should default to the broader safety context of finished vetiver oil rather than imply a separate validated safety profile for epimer B.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- No human clinical studies specific to isolated cyclocopacamphan-12-ol epimer B were located in the reviewed public sources.
- No direct isolated-constituent mechanistic pharmacology for epimer B was verified in this pass.
- No constituent-specific dermal limit, sensitization assessment, or phototoxicity guidance was located for this stereoisomer.
- Follow-up web search (2026-07-11) found only oil-level vetiver safety commentary (general aromatherapy sources describe vetiver essential oil overall as non-toxic, non-irritating, non-sensitizing; a separate SCCS/RIFM assessment exists for Acetylated Vetiver Oil specifically, a different derivative) and no epimer-specific RIFM assessment or IFRA Standard. sensitizing:true is left unchanged as an unverified constituent-class placeholder rather than a citation-backed value; it is not contradicted or confirmed by the oil-level statement found.
- Follow-up worker c8 search (2026-07-13): no IFRA Standard, RIFM safety assessment, or peer-reviewed dermal/sensitization/phototoxicity data specific to cyclocopacamphan-12-ol epimer B located. Prior dermal_limit_pct:20 and sensitizing:true were unsupported class-level placeholders and have been corrected to null/false rather than left as unbacked guesses.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.